Tina Fascetti is the mid-sized agency's new Chief Creative Officer. CEO Matt Brown (and ICC Lowe alum) tells MM&M the new Guidemark is just getting started.
Stop trying to sell your edgy work as a TV spot. By finding a backdoor through digital, risky work can often see the light of day, says one ad consultant.
Pharma ad budgets are growing, says IPG; Medical device tax debate rages on; Pfizer has PCSK9 pill in the works.
Havas Group has expanded its footprint in Germany, acquiring Bird & Schulte.
Siren, one of the most experienced agencies in the rare-disease space, will add its patient-outreach expertise to new owner Dohmen's patient-care model.
"Technology is evolving in a way that will make your detailing experiences even more meaningful. 2015 will bring in some exciting and innovative products..."
The annual awards show, celebrating creativity in marketing communications, has named Langland's executive creative director and Sudler & Hennessey chief creative officer to lead the jury.
"Customer service is more than just a nice-to-have. In this competitive marketplace, it can mean the difference between your brand or someone else's."
With the purchase of Olson Communications, the agency aims to serve clients eager for expertise from outside the healthcare industry.
Success today is predicated on recognizing that every patient is different, every disease is different, every drug, every breakthrough and every cure is different.
Top 100 Agency Profiles
Click here to access the profiles
Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.
- Novartis psoriasis drug approval could upend market
- Sandoz gets ready to make the biosimilar case with oncologists
- Guidemark Health jumpstarts rebrand, brings on big-agency grad
- MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics
- Nurse practitioner workforce has just about doubled